Influenza hemagglutinin and neuraminidase variants

Abstract

Polypeptides, polynucleotides, methods, compositions, and vaccines comprising (avian pandemic) influenza hemagglutinin and neuraminidase variants are provided.

1 . A reassortant influenza virus, wherein said virus comprises 6 internal genome segments from one or more donor viruses other than A/Ann Arbor/6/60 and at least one genome segment encoding an immunogenic influenza surface antigen comprising an amino acid sequence selected from the group consisting of: SEQ ID NO: 13, 14, 19 and 20. 
     
     
         2 . The reassortant influenza virus of  claim 1 , wherein the 6 internal genome segments of the one or more donor viruses comprise one or more phenotypic attributes selected from the group consisting of: attenuated, cold adapted and temperature sensitive. 
     
     
         3 . The reassortant influenza virus of  claim 1 , wherein said one or more donor viruses are PR8. 
     
     
         4 . The reassortant influenza virus of  claim 1 , wherein said one or more donor viruses are A/Leningrad/17. 
     
     
         5 . An immunogenic composition comprising an immunologically effective amount of the reassortant influenza virus of  claim 1 . 
     
     
         6 . An immunogenic composition comprising an immunologically effective amount of the reassortant influenza virus of  claim 2 . 
     
     
         7 . An immunogenic composition comprising an immunologically effective amount of the reassortant influenza virus of  claim 3 . 
     
     
         8 . An immunogenic composition comprising an immunologically effective amount of the reassortant influenza virus of  claim 4 . 
     
     
         9 . A method for stimulating the immune system of a subject to produce a protective immune response against influenza virus, the method comprising administering to the subject an immunologically effective amount of the reassortant influenza virus of  claim 1  in a physiologically effective carrier. 
     
     
         10 . A method for stimulating the immune system of a subject to produce a protective immune response against influenza virus, the method comprising administering to the subject an immunologically effective amount of the reassortant influenza virus of  claim 2  in a physiologically effective carrier. 
     
     
         11 . A method for stimulating the immune system of a subject to produce a protective immune response against influenza virus, the method comprising administering to the subject an immunologically effective amount of the reassortant influenza virus of  claim 3  in a physiologically effective carrier. 
     
     
         12 . A method for stimulating the immune system of a subject to produce a protective immune response against influenza virus, the method comprising administering to the subject an immunologically effective amount of the reassortant influenza virus of  claim 4  in a physiologically effective carrier. 
     
     
         13 . A method of prophylactic or therapeutic treatment of a viral infection in a subject, the method comprising: administering to the subject the virus of  claim 1  in an amount effective to produce an immunogenic response against the viral infection. 
     
     
         14 . A method of prophylactic or therapeutic treatment of a viral infection in a subject, the method comprising: administering to the subject, the virus of  claim 3  in an amount effective to produce an immunogenic response against the viral infection. 
     
     
         15 . A method of prophylactic or therapeutic treatment of a viral infection in a subject, the method comprising: administering to the subject, the virus of  claim 4  in an amount effective to produce an immunogenic response against the viral infection. 
     
     
         16 . The method of  claim 13 , wherein said virus is killed or inactivated. 
     
     
         17 . The method of  claim 14 , wherein said virus is killed or inactivated. 
     
     
         18 . The method of  claim 15 , wherein said virus is killed or inactivated. 
     
     
         19 . The method of  claim 9 , wherein the subject is a human. 
     
     
         20 . The method of  claim 10 , wherein the subject is a human. 
     
     
         21 . The method of  claim 11 , wherein the subject is a human. 
     
     
         22 . A live attenuated influenza vaccine comprising the composition of  claim 5 . 
     
     
         23 . A live attenuated influenza vaccine comprising the composition of  claim 6 . 
     
     
         24 . A split virus of killed virus vaccine comprising the immunogenic composition of  claim 5 . 
     
     
         25 . A split virus or killed virus vaccine comprising the immunogenic composition of  claim 6 . 
     
     
         26 . A method for producing influenza viruses in cell culture, the method comprising:
 i) introducing into a population of host cells a plurality of vectors comprising nucleic acid sequences corresponding to:
 a) at least 6 internal genome segments from a donor virus other than A/Ann Arbor/6/60 and at least one genome segment encoding an immunogenic influenza surface antigen comprising an amino acid sequence selected from the group consisting of: SEQ ID NO: 13, 14, 19 and 20; or 
 b) at least 6 internal genome segments from a donor virus other than A/Ann Arbor/6/60, wherein said donor virus has one or more phenotypic attributes selected from the group consisting of: attenuated, cold adapted and temperature sensitive; and at least one genome segment encoding an immunogenic influenza surface antigen comprising an amino acid sequence selected from the group consisting of: SEQ ID NO: 13, 14, 19 and 20; 
   ii) culturing the population of host cells at a temperature less than or equal to 35° C.; and,   iii) recovering a plurality of influenza viruses.   
     
     
         27 . An immunogenic composition comprising an immunologically effective amount of the influenza virus produced by the method of  claim 26 . 
     
     
         28 . A method for stimulating the immune system of an individual to produce a protective immune response against influenza virus, the method comprising administering to the individual an immunologically effective amount of the influenza virus produced by the method of  claim 26  in a physiologically effective carrier. 
     
     
         29 . A method for stimulating the immune system of an individual to produce a protective immune response against influenza virus, the method comprising administering to the individual the immunogenic composition of  claim 27 . 
     
     
         30 . A method of prophylactic or therapeutic treatment of a viral infection in a subject, the method comprising: administering to the subject the virus of  claim 2  in an amount effective to produce an immunogenic response against the viral infection.